Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in…
<!-- Name:DistributionId Value:8781004 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Browsing Tag
Applied Molecular Transport Inc.
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of…
– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was well-tolerated – Planned Phase 1b trial for the company’s second clinical asset, AMT-126, in UC…
Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight…
Publication describes critical interactions between cholix-based transport domain and endogenous intracellular trafficking pathways used by Company’s proprietary biologic product candidates to cross intestinal epithelial barrier Deep…
Applied Molecular Transport Announces Upcoming Investor Events in September and October
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the following…